| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/08/2004 | US20040132053 Sphingosine kinase enzyme |
| 07/08/2004 | US20040132038 Membrane protein for use as diagnostic tool in the detection and prevention of cell proliferative, cardiovascular, skin, nervous system, respiratory and metabolic disorders |
| 07/08/2004 | US20040131703 Antiinflammatory agents; respiratory system disorders |
| 07/08/2004 | US20040131702 Mixture with acid |
| 07/08/2004 | US20040131692 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 07/08/2004 | US20040131671 Sustained release formulations containing acetaminophen and tramadol |
| 07/08/2004 | US20040131596 Method and compositions for modifying target receptor function associated with neurological disorders |
| 07/08/2004 | US20040131593 Neuronal gene transfer |
| 07/08/2004 | US20040131585 Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 07/08/2004 | US20040131583 Biocompatible polymers, process for their preparation and compositions containing them |
| 07/08/2004 | US20040131545 Anticholesterol agents |
| 07/08/2004 | DE202004005959U1 Arzneimittel Drug |
| 07/08/2004 | DE19906979B4 Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit Use of deoxypeganine for the treatment of nicotine dependence |
| 07/08/2004 | DE19906978B4 Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit Pharmaceutical composition containing deoxypeganine for the treatment of drug addiction |
| 07/08/2004 | DE10261808A1 Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen Use of L-DOPA, its derivatives and these compounds containing drug for the prophylaxis of psychotic disorders |
| 07/08/2004 | CA2800237A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 07/08/2004 | CA2513077A1 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| 07/08/2004 | CA2511340A1 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| 07/08/2004 | CA2511142A1 Escitalopram hydrobromide and a method for the preparation thereof |
| 07/08/2004 | CA2510750A1 A process for preparing duloxetine and intermediates for use therein |
| 07/08/2004 | CA2510471A1 Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| 07/08/2004 | CA2508657A1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 07/08/2004 | CA2502138A1 Therapeutic applications of 2-substituted 4-heteroarylryrimidines |
| 07/07/2004 | EP1435521A1 Detection and diagnosis of transmissible spongiform encephalopathies |
| 07/07/2004 | EP1435353A1 Novel heterocyclic compound and anti-inflammatory agent |
| 07/07/2004 | EP1435237A1 Prevention of migraine recurrence |
| 07/07/2004 | EP1434990A2 Method for identifying compounds the specifically deplete mast cells |
| 07/07/2004 | EP1434886A2 Mid 241 receptor, a novel g-protein coupled receptor |
| 07/07/2004 | EP1434865A2 Variants and exons of the glyt1 transporter |
| 07/07/2004 | EP1434863A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS |
| 07/07/2004 | EP1434860A2 Enzymes |
| 07/07/2004 | EP1434801A2 Treatment for central nervous system disorders |
| 07/07/2004 | EP1434798A2 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 07/07/2004 | EP1434796A2 Secreted proteins |
| 07/07/2004 | EP1434792A2 Peptidyl ketones as inhibitors of dpiv |
| 07/07/2004 | EP1434788A2 Proteins associated with cell growth, differentiation, and death |
| 07/07/2004 | EP1434787A2 Lp mammalian proteins; related reagents |
| 07/07/2004 | EP1434785A2 Protein modification and maintenance molecules |
| 07/07/2004 | EP1434777A1 Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system |
| 07/07/2004 | EP1434775A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 07/07/2004 | EP1434774A1 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| 07/07/2004 | EP1434773A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 07/07/2004 | EP1434769A2 Compounds useful as reversible inhibitors of cysteine proteases |
| 07/07/2004 | EP1434766A1 Piperidine compounds as muscarinic antagonists |
| 07/07/2004 | EP1434763A2 Beta-lactamyl vasopressin v1a antagonists |
| 07/07/2004 | EP1434762A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 07/07/2004 | EP1434756A1 Novel compounds |
| 07/07/2004 | EP1434624A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 07/07/2004 | EP1434599A1 Human 3 relaxin |
| 07/07/2004 | EP1434597A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/07/2004 | EP1434594A1 Cyclosporin analogs for the treatment of autoimmune diseases |
| 07/07/2004 | EP1434588A2 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 07/07/2004 | EP1434583A1 N-aroyl piperazine derivatives as orexin receptor antagonists |
| 07/07/2004 | EP1434581A1 3- hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 07/07/2004 | EP1434580A2 Allylamides useful in the treatment of alzheimer's disease |
| 07/07/2004 | EP1434579A1 Imidazole derivatives as antiinflammatory agents |
| 07/07/2004 | EP1434578A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 07/07/2004 | EP1434577A1 Pyrrolidinone derivatives |
| 07/07/2004 | EP1434575A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
| 07/07/2004 | EP1434572A2 Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles |
| 07/07/2004 | EP1401431A4 Human growth hormone antagonists |
| 07/07/2004 | EP1242404B1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 07/07/2004 | EP1235827B1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 07/07/2004 | EP1230222B1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/07/2004 | EP1218359B1 Piperazine compounds as tachykinins antagonists |
| 07/07/2004 | EP1087971B1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 07/07/2004 | EP1071670B1 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| 07/07/2004 | EP1006794A4 A method for treating or preventing alzheimer's disease |
| 07/07/2004 | EP0967978B1 Combined preparation of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol |
| 07/07/2004 | CN1511157A Novel pyrrole derivatives as pharmaceutical agents |
| 07/07/2004 | CN1511155A Amido ether substituted imidazoquinolines |
| 07/07/2004 | CN1511154A Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease |
| 07/07/2004 | CN1511149A 2-thio-substituted imidazole derivatives and use therof in pharmaceutical industry |
| 07/07/2004 | CN1511141A Method for preparation of 10,11-dihydro-10-hydroxy-5H-dibenz/B, F/azepine-5-carboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B, F/azepine-5-carboxamide |
| 07/07/2004 | CN1511137A Hydro phobic polyamine analogs and methods for their use |
| 07/07/2004 | CN1511053A HSA-free formulations of interferon-Beta |
| 07/07/2004 | CN1511043A Pregabalin lactose conjugates |
| 07/07/2004 | CN1511040A Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 07/07/2004 | CN1511038A Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 07/07/2004 | CN1511031A Solid pharmaceutical formulations comprising modafinil |
| 07/07/2004 | CN1511030A Abuse resistant pharmaceutical composition containing capsaicin |
| 07/07/2004 | CN1511029A Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D] pyrimidine for treatment of pain |
| 07/07/2004 | CN1511026A Granular preparations of gaboxadol |
| 07/07/2004 | CN1510037A Cornel extractive, extracting method and use for preparing medicine and health food |
| 07/07/2004 | CN1510034A Indazole compound, preparing method thereof and medicine composition containing the same |
| 07/07/2004 | CN1509751A Medicinal composition for improving sleep |
| 07/07/2004 | CN1509744A Preparation of Gebai liquid for sober up |
| 07/07/2004 | CN1509737A Chinese medicinal composition with delaying senility and improving sleep functions, and preparing method thereof |
| 07/07/2004 | CN1509731A Instant plant composition for sobering up and preparing method thereof |
| 07/07/2004 | CN1509713A Indole derivative use as 5HT1 antagonist agent |
| 07/07/2004 | CN1156462C Antipsychotic cyclic N-aralkyl amines |
| 07/07/2004 | CN1156454C Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/07/2004 | CN1156452C Compound as anti-inflammatory agent |
| 07/07/2004 | CN1156451C Betz 2-adrenoceptor agonists |
| 07/07/2004 | CN1156448C Optical isomer of 3-methyl fentanyl, derivant, synthesizing and its analgesic activity |
| 07/07/2004 | CN1156445C Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isindoline derivatives |
| 07/07/2004 | CN1156299C Health-care tea as cigarette companion and its preparation method |
| 07/07/2004 | CN1156286C Chinese medicine for treating disease and improving intelligence |
| 07/06/2004 | US6759536 Genetic engineering; polyketides |
| 07/06/2004 | US6759535 A 3-amide-methyl- or 3-urea-isoquinoline derivatives, enzyme inhibitor of protein kinase, for treating cell proliferation, cell death, inflammatory diseases, autoimmune diseases, bone disorders, infectious diseases, viral diseases |